Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "Development"

4225 News Found

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery
R&D | February 11, 2026

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research


Veradermics completes enrollment in both Phase 3 male hair loss trials
Clinical Trials | February 11, 2026

Veradermics completes enrollment in both Phase 3 male hair loss trials

The milestone means more than 1,000 men are now enrolled across both Phase 3 programs


Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion
News | February 10, 2026

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion

The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles


Motorica showcases advanced prosthetics expertise at OPAI National Conference
Technology | February 10, 2026

Motorica showcases advanced prosthetics expertise at OPAI National Conference

Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting


Zydus Lifesciences reports strong Q3 & 9M FY26 growth
News | February 10, 2026

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million


Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
News | February 09, 2026

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26


Biomica seals exclusive global license for groundbreaking microbiome cancer therapy
News | February 09, 2026

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer


Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
Clinical Trials | February 07, 2026

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke